FindTrial
Sign In

Automatic PD-L1 immunohistochemistry evaluation system for non-small cell lung cancer based on deep learning

Establishment and evaluation of PD-L1 immunohistochemical automatic evaluation system for non-small cell lung cancer immunotherapy based on deep learning

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036028
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Gold Standard:The consistency between PD-L1 pathologist's interpretation and artificial intelligence interpretation was not less than 0.8
Index test:PD-L1&#32
immunohistochemical&#32
staining
&#32
artificial&#32
intelligence
paraffin&#32
embedded&#32
specimens&#32
of&#32
non-small&#32
cell&#32
lung&#32
cancer

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Complete clinical data and pathological information; 2. Patients who signed written informed consent to participate in the study; 3. Sections of NSCLC stained with PD-L1 immunohistochemistry; 4. The number of tumor cells under microscope is more than 100.

Exclusion criteria

Exclusion criteria: 1. Preoperative treatment (neoadjuvant chemotherapy or radiotherapy); 2. metastatic lung cancer.

Design outcomes

Primary

MeasureTime frame
consistency (Kappa);—

Countries

China

Contacts

Public ContactYuan Li

Fudan University Shanghai Cancer Center

lumoxuan2009@163.com+86 18017317261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026